Association between uterine serous carcinoma and breast cancer

被引:38
作者
Gehrig, PA
Bae-Jump, VL
Boggess, JF
Groben, PA
Fowler, WC
Van Le, L
机构
[1] Univ N Carolina, Div Gynecol Oncol, Dept Obstet & Gynecol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA
关键词
endometrial cancer; breast cancer; tamoxifen;
D O I
10.1016/j.ygyno.2004.04.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Endometrial cancer and breast cancer are two common malignancies found in women. As a result of estrogen dependency, an association is thought to exist between these entities. This study was undertaken to determine if the endometrial carcinomas, which develop in women with a history of breast cancer, were more likely to be of the endometrioid or the serous histology, which is generally considered non-estrogen-dependent. Methods. A retrospective chart review was conducted for the years 1984-2001. All women who were diagnosed at our institution with endometrial carcinoma were identified. The women who also had a prior history of breast cancer were identified and comprise the cohort for this study. Information regarding age at diagnosis, tumor stage, histologic subtype, and tamoxifen exposure were recorded and analyzed. Results. About 1,166 women were diagnosed with endometrial cancer during the study period, of whom 54 (4.6%) had a pre-existing diagnosis of breast cancer. Of the 54 women in this study, 41 had tumors of the endometrioid histology and 13 had a tumor of the serous subtype. There was no difference with regards to median age at the time of diagnosis or years of tamoxifen exposure. Women with breast cancer were more likely to develop uterine serous carcinoma (USC) as compared to one of endometrioid histology (OR 2.6; 95% CI 1.29-5.23). Conclusions. Women with breast cancer who subsequently developed endometrial cancer exhibited a 2.6-fold increased risk of developing a USC as compared to an endometrioid carcinoma. These findings suggest that there may be an underlying genetic predisposition linking breast cancer and USC. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:208 / 211
页数:4
相关论文
共 17 条
[1]  
*AM CANC SOC INC, 2004, CANC FACTS FIG 2004
[2]   A genetic epidemiological study of carcinoma of the fallopian tube [J].
Aziz, S ;
Kuperstein, G ;
Rosen, B ;
Cole, D ;
Nedelcu, R ;
McLaughlin, J ;
Narod, SA .
GYNECOLOGIC ONCOLOGY, 2001, 80 (03) :341-345
[3]   BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum [J].
Bandera, CA ;
Muto, MG ;
Schorge, JO ;
Berkowitz, RS ;
Rubin, SC ;
Mok, SC .
OBSTETRICS AND GYNECOLOGY, 1998, 92 (04) :596-600
[4]   TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES [J].
BARAKAT, RR ;
WONG, G ;
CURTIN, JP ;
VLAMIS, V ;
HOSKINS, WJ .
GYNECOLOGIC ONCOLOGY, 1994, 55 (02) :164-168
[5]   The endometrial effects of SERMs [J].
Cano, A ;
Hermenegildo, C .
HUMAN REPRODUCTION UPDATE, 2000, 6 (03) :244-254
[6]   Hormonal pathology of the endometrium [J].
Deligdisch, L .
MODERN PATHOLOGY, 2000, 13 (03) :285-294
[7]   ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14 [J].
FISHER, B ;
COSTANTINO, JP ;
REDMOND, CK ;
FISHER, ER ;
WICKERHAM, DL ;
CRONIN, WM ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
EVANS, J ;
FARRAR, W ;
KAVANAH, M ;
LICKLEY, HL ;
MARGOLESE, R ;
PATERSON, AHG ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07) :527-537
[8]   Noninvasive papillary serous carcinoma of the endometrium [J].
Gehrig, PA ;
Groben, PA ;
Fowler, WC ;
Walton, LA ;
Van le, L .
OBSTETRICS AND GYNECOLOGY, 2001, 97 (01) :153-157
[9]   Papillary serous carcinoma of the uterus: Increased risk of subsequent or concurrent development of breast carcinoma [J].
Geisler, JP ;
Sorosky, JI ;
Duong, HL ;
Buekers, TE ;
Geisler, MJ ;
Sood, AK ;
Anderson, B ;
Buller, RE .
GYNECOLOGIC ONCOLOGY, 2001, 83 (03) :501-503
[10]   Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? [J].
Goshen, R ;
Chu, W ;
Elit, L ;
Pal, T ;
Hakimi, J ;
Ackerman, I ;
Fyles, A ;
Mitchell, M ;
Narod, SA .
GYNECOLOGIC ONCOLOGY, 2000, 79 (03) :477-481